Credit score: Cliff Sales space from Pexels
Researchers are working to cut back the well being dangers related to Down syndrome and enhance long-term high quality of life.
David Clarke has a busy life juggling two jobs. He works three days per week recycling waste at a grocery store in Drogheda, his hometown in jap Eire. On different days, he takes the hour-long bus journey to the capital Dublin to work in a present hamper warehouse. Aged 44 and dwelling with Down syndrome, David is flourishing.
“He still lives at home with myself and his mother, but he has a pretty independent life,” mentioned his father, Pat Clarke, who volunteers on the board of the European Down Syndrome Affiliation (EDSA), a non-profit group supporting and representing individuals with Down syndrome throughout Europe.
Elevated well being dangers
Each life and job prospects for these with the situation have considerably improved in current many years, aided by medical advances and advocacy by the likes of EDSA.
“When David was born in 1981, the life expectancy of someone with Down syndrome in Ireland was only in the mid-20s,” mentioned Clarke. “Now, it’s 60 to 70.”
However there may be nonetheless a lot room for enchancment. Whereas David Clarke’s present state of affairs is optimistic, many challenges stay for individuals dwelling with Down syndrome.
With an extended lifespan comes an elevated danger of Down syndrome-associated well being circumstances, together with early-onset Alzheimer’s and a higher danger of weight problems. The situation may trigger lifelong developmental delays, cognitive impairment and extreme well being points, together with coronary heart and digestive issues.
Dr. Yann Hérault, a geneticist and neurobiologist on the Institute of Genetics, Molecular and Mobile Biology in Strasbourg, France, is main a five-year analysis initiative referred to as GO-DS21 that’s working to raised perceive the distinctive well being dangers of individuals with Down syndrome and how one can handle them.
“We weren’t previously aware of exactly when and how many of these comorbidities were appearing during the lifetime of people with Down syndrome, or how they were linked together,” mentioned Hérault. “It’s necessary to know this to understand the syndrome as a whole.”
Understanding illness mechanisms
The GO-DS21 workforce brings collectively clinicians, pathophysiologists, integrative bioinformaticians and synthetic intelligence pc scientists from France, Germany, the Netherlands, Spain and the U.Ok.
Collectively they’re exploring the total vary of well being points confronted by individuals with Down syndrome, with a specific deal with weight problems, diabetes and mental incapacity.
For example, their investigations discovered that diabetes danger for individuals with Down syndrome was 4 instances that of the overall inhabitants in 5- to 24-year-olds and double in 25- to 44-year-olds. Nevertheless, diabetes doesn’t look like a big issue within the growth of weight problems in individuals with Down syndrome—suggesting that different organic and genetic elements might play a task.
The analysis workforce additionally found the next danger of dementia, hypothyroidism, epilepsy and leukemia, however a decrease prevalence of bronchial asthma, sure cancers, ischemic coronary heart illness and hypertension.
Their work will assist construct a clearer image of the actual well being profile of individuals with Down syndrome, together with each the genetic and environmental elements contributing to the totally different circumstances they face.
Enhancing high quality of life
By understanding the organic pathways and mechanisms concerned that join Down syndrome with totally different circumstances, the researchers hope to have the ability to supply more practical remedies and well being recommendation that might assist enhance their total high quality of life.
The analysis is especially necessary because the situation is seemingly turning into extra widespread, growing from an estimated 16 instances per 10,000 births in 1990 to 23 in 2015, in line with information from the European Fee’s JRC-EUROCAT central registry.
“The idea is to give families evidence-based recommendations of things they can do to minimize the health risks of people with Down syndrome,” mentioned Hérault.
To this finish, the researchers maintain common conferences with affected person organizations similar to EDSA to share outcomes and get suggestions. This feeds into the EU’s purpose to make impartial dwelling for individuals with disabilities a actuality, empowering them to decide on how, the place and with whom they stay.
Because the workforce learns extra in regards to the elements influencing the well being of individuals with Down syndrome, they’re compiling way of life suggestions on food plan and train that they imagine may make a giant distinction.
The analysis workforce has additionally launched a serious survey to coincide with World Down Syndrome Day on 21 March, aiming to gather data from households that may assist additional inform their analysis and, in the end, enhance the lives of individuals with Down syndrome.
Increasing therapy choices
On the therapy facet, one other analysis workforce beneath the course of Dr. Rafael de la Torre, a neuroscientist on the Hospital del Mar Analysis Institute in Barcelona, Spain, is making promising progress on growing a pharmacological resolution to enhance cognitive impairment in individuals with Down syndrome.
As a part of a five-year worldwide analysis effort referred to as ICOD, Aelis Farma, a biotech firm in Bordeaux, France, is engaged on an experimental drug referred to as AEF0217 that targets part of the mind taking part in a task in reminiscence and studying—the CB1 receptor.
This receptor is liable to extreme exercise in these with Down syndrome, which is believed to contribute to cognitive impairments. AEF0217 acts as a selective CB1 inhibitor, lowering this overactivity with out blocking the receptor fully.
Potential advantages for individuals with Down syndrome embrace enhanced cognitive talents, particularly in studying and reminiscence, and higher independence in each day life because of enhancements in focus and problem-solving.
AEF0217 is presently in scientific trials, with early outcomes displaying promising outcomes. If profitable, it could possibly be the primary permitted therapy to boost cognitive perform in individuals with Down syndrome.
“This is the first time that we have in our hands a treatment with the potential to really improve intellectual disability in people with Down syndrome,” mentioned de la Torre. “That will help them integrate better into society and have better work opportunities.”
Quick motion
A serious step was taken in an preliminary month-long trial in 2024 that appeared to indicate each the protection of the drug and its potential effectiveness.
Amongst 29 individuals with Down syndrome aged between 18 and 35 with delicate or average incapacity, it resulted in vital enhancements in verbal and written communication, each day dwelling expertise and social interactions. Individuals additionally confirmed higher flexibility in adapting to new conditions.
“These effects were seen in just four weeks, which is fantastic,” mentioned de la Torre. “Typically, with a treatment for cognitive functions, you would expect to wait about three to six months to observe improvements.”
By the point the five-year ICOD initiative ends in January 2026, the workforce may have accomplished a bigger trial on round 200 contributors throughout France, Italy and Spain. De la Torre believes the drug could possibly be prepared to be used inside about three years if fast-tracked.
Aside from having the potential to enhance the life of individuals with Down syndrome, a therapy like this might additionally considerably cut back the stress of fogeys, he mentioned. “Having a treatment will change everything.”
Supplied by
Horizon: The EU Analysis & Innovation Journal
Quotation:
Dwelling longer, dwelling higher: New advances in Down syndrome care (2025, March 20)
retrieved 20 March 2025
from https://medicalxpress.com/information/2025-03-longer-advances-syndrome.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
